Arvinas, Inc. (ARVN) closed the last trading session at $17.70, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
Shares of Arvinas, Inc. (ARVN) have gained 0.5% over the past four weeks to close the last trading session at $17.67, but there could still be a solid upside left in the stock if short-term price ...
Handelsbanken Fonder AB boosted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 16.9% in the fourth quarter, according to the company in its most recent Form 13F filing with ...
ARVN stock opened at $17.50 on Thursday. The firm has a 50-day moving average price of $18.28 and a 200-day moving average price of $22.53. Arvinas has a 12 month low of $15.53 and a 12 month high ...
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.
Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform. Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors. Uncover ...
Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor ...
If that’s not quite your speed, then keep reading. We’ve got a few more top-notch waterproof backpacks to cover your needs. When shopping for waterproof backpacks, it’s important to read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results